Investigation of FJ 194940.1 gene alternative splicing in colon cancer and its association with clinicopathological parameters
- Authors:
- Malwina Bartczak-Tomczyk
- Aleksandra Sałagacka
- Marek Mirowski
- Ewa Balcerczak
View Affiliations
Affiliations: Laboratory of Molecular Biology and Pharmacogenomics, Department of Pharmaceutical Biochemistry, Medical University of Lodz, Lodz 90-151, Poland
- Published online on: November 9, 2011 https://doi.org/10.3892/etm.2011.378
-
Pages:
237-242
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Abstract
Colorectal cancer (CRC) is one of the most frequent neoplasms and is responsible for the second highest mortality rate of all cancers in the more developed regions of the world. The molecular mechanisms of CRC are relatively well characterized and are correlated to the accumulation of genetic mutations and certain patterns of gene expression/over-expression. There are a number of possible molecular factors involved in CRC progression in the aforementioned pathways, which are as yet not well described. One of these factors appears to be the gene FJ 194940.1, previously termed P65. FJ 194940.1 consists of 6 exons and probably undergoes alternative splicing in malignant tissues. In this study, tissue samples from 102 patients with colon cancer were investigated to confirm alternative splicing and to correlate results obtained with clinicopathological parameters. A total of 18 splice variants, which arise from various combinations of 4 exons (II, III, IV and V) and exon-exon junctions between exons 1 and 2 (I/II); 2 and 3 (II/III); 3 and 4 (III/IV), as well as 4 and 5 (IV/V), were found. For statistical analysis the full length transcript was divided into parts A and B. Part A consisted of exons II and III, as well as I/II and II/III exon-exon junctions, whereas part B comprised exons IV and V, as well as III/IV and IV/V exon‑exon junctions. The expression of part B of the FJ 194940.1 gene transcript is correlated with well-differentiated (G1) and moderately differentiated cases (G2). Lymphocytic tumor infiltration, a good prognostic factor in CRC, was significantly correlated to the presence of all elements in part A of the FJ 194940.1 gene transcript. Patients who had all elements in part A of the transcript survived for a shorter duration. Investigation of the FJ 194940.1 gene revealed that the gene had undergone alternative splicing. However, the role of its transcripts and potential proteins should be examined in detail.
View References
|
1.
|
E BalcerczakM BalcerczakM
MirowskiQuantitative analysis of the p65 gene expression in
patients with colorectal cancerInt J Biomed
Sci3287291200723675055
|
|
2.
|
E BalcerczakJ BartkowiakJZ BłońskiT RobakM
MirowskiExpression of gene encoding p65 oncofetal protein in acute
and chronic leukemiasNeoplasma49295299200212458326
|
|
3.
|
W CzyżE BalcerczakM RudowiczH
NiewiadomskaZ PasiekaK KuzdakM MirowskiExpression of C-ERBB2 and
P65 genes and their protein products in follicular neoplasms of
thyroid glandFol Histochem Cytobiol419195200312722795
|
|
4.
|
E BalcerczakT MalewskiM BartczakM
MirowskiAlternation of FJ 194940.1 transcript expression after
provirus integration in human neoplasmInt J Integrat
Biol1158632011
|
|
5.
|
B Kwabi-AddoF RopiquetD GiriM
IttmannAlternative splicing of fibroblast growth factor receptors
in human prostate
cancerProstate46163172200110.1002/1097-0045(20010201)46:2%3C163::AID-PROS1020%3E3.0.CO;2-T11170144
|
|
6.
|
P ChomczynskiN SacchiSingle-step method of
RNA isolation by acid guanidinium thiocyanate-phenol-chloroform
extractionAnal
Biochem1621569198710.1016/0003-2697(87)90021-22440339
|
|
7.
|
TI OrbanE OlahExpression profiles of BRCA1
splice variants in asynchronous and in G1/S synchronized tumor cell
linesBiochem Biophys Res
Commun2803238200110.1006/bbrc.2000.406811162473
|
|
8.
|
D BaudryM HamelinMO CabanisJC FournetMF
TournadeS SarnackiC JunienC JeanpierreWT1 splicing alterations in
Wilms’ tumorsClin Cancer Res6395739652000
|
|
9.
|
M MixonF KittrellD MedinaSplice variant
expression of CD44 in patients with breast and ovarian cancerOncol
Rep8145151200111115587
|
|
10.
|
M HoriJ ShimazakiS InagawaM ItabashiM
HoriAlternatively spliced MDM2 transcripts in human breast cancer
in relation to tumor necrosis and lymph node involvementPathol
Int50786792200010.1046/j.1440-1827.2000.01119.x11107050
|
|
11.
|
Y XinA GraceMM GallagherBT CurranMB
LeaderEW KayCD44v6 in gastric carcinoma: a marker of tumor
progressionAppl Immunohistochem Mol
Morphol9138142200110.1097/00129039-200106000-0000611396631
|
|
12.
|
S AaltomaaP LipponenM Ala-OpasVM
KosmaExpression and prognostic value of CD44 standard and variant
v3 and v6 isoforms in prostate cancerEur
Urol39138144200110.1159/00005242811223672
|
|
13.
|
J RysA KruczakB LackowskaA
Jaszcz-GruchałaA BrandysA StelmachM ReinfussThe role of CD44v3
expression in female breast carcinomasPol J
Pathol54243247200314998292
|
|
14.
|
SM HewittGF SaundersDifferentially spliced
exon 5 of the Wilms’ tumor gene WT1 modifies gene
functionAnticancer Res1662162619968687106
|
|
15.
|
C EnglertX HouS MaheswaranWT1 suppresses
synthesis of the epidermal growth factor receptor and induces
apoptosisEMBO J144662467519957588596
|
|
16.
|
M BalcerczakE BalcerczakG Pasz-WalczakR
KordekM MirowskiExpression of the p65 gene in patients with
colorectal cancer: comparison with some histological typing,
grading and clinical stagingEur J Surg
Oncol30266270200410.1016/j.ejso.2003.11.00615028307
|
